343 results on '"Holyoake T"'
Search Results
2. Identifying genes and pathways deregulated in chronic myeloid leukaemia stem cells through meta-analysis of transcriptomic data: 297
3. Small molecule Axl inhibitor BGB324 inhibits primary chronic phase chronic myeloid leukaemia (CML) cell function and viability: 289
4. Uncovering the BCR-ABL1 tyrosine kinase independent signature in chronic myeloid leukaemia stem cells: 291
5. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression: 284
6. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia - 2 year follow up: 27
7. The autophagy related protein ATG7 regulates differentiation and energy metabolism of CML cells: 9
8. Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia
9. A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5
10. Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1
11. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
12. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
13. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
14. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML: 1
15. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
16. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
17. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
18. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry
19. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT)
20. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro
21. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia
22. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease
23. Dysregulated expression of the major telomerase components in leukaemic stem cells
24. A prospective study of real-time panfungal PCR for the early diagnosis of invasive fungal infection in haemato-oncology patients
25. Targeting survival pathways in chronic myeloid leukaemia stem cells
26. ‘Druggable’ autophagy genes are suppressed in CML stem/progenitor cells compared to their normal counterparts and up-regulated following Bcr-Abl inhibition: 34
27. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia
28. Identification of the key survival pathways underlying CML stem cell resistance to TKIs: 3
29. Ponatinib and inhibition of the PI3K/Akt/mTOR pathway induces cell death and protective autophagy in TKI-resistant CML stem/progenitor cells: 2
30. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34 + CML stem/progenitor cells
31. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
32. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response
33. Nuclear entrapment of BCR–ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells
34. The farnesyl transferase inhibitor BMS-214662 selectively targets primary CML stem cells trough activation of caspases: 322
35. Bortezomib has anti-proliferative and apoptotic effects against quiescent CML stem cells and cells expressing the T3151 mutation: 159
36. Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency
37. HOX genes are a major target for epigenetic mis-regulation in adult and childhood leukaemia: 236
38. Human neutrophil elastase is not a target for therapy in chronic myeloid leukaemia
39. Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia
40. Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome
41. The novel, dual Src/Bcr-Abl kinase inhibitor, BMS-354825, does not overcome the intrinsic insensitivity of quiescent chronic myeloid leukaemia stem cells to imatinib: 245
42. Fatal peripheral neuropathy following FLA chemotherapy
43. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation
44. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapy-related infections
45. Reduced hTR expression in CML CD34+ cells at diagnosis: a novel mechanism for telomere loss in leukaemia
46. Real time PCR is superior to ELISA for the early detection of invasive fungal infection in haematology patients
47. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones
48. A SPECTRUM OF SKIN REACTIONS CAUSED BY THE TYROSINE KINASE INHIBITOR IMATINIB MESYLATE (STI 571, GLIVEC®)
49. Real-time PCR is superior to galactomannan and mannan ELISA for the early detection of invasive fungal infection in hematology patients
50. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.